Andreas Halvorsen’s Sage Therapeutics SAGE Stock Holding History

Andreas Halvorsen’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-263,466	Closed	-$37M	–	76
2019 Q3	$37M	Buy	+263,466	New	+$44.1M	0.19%	52

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Andreas Halvorsen's SAGE Position: Q4 2019 in Review

Andreas Halvorsen sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 263,466 shares — an estimated $37M sold.

Andreas Halvorsen first reported a position in SAGE in Q3 2019 and held it in 1 quarter. The position peaked at $37M in Q3 2019. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Andreas Halvorsen reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Andreas Halvorsen sold 263,466 Sage Therapeutics shares in Q4 2019, an estimated $37M.
Andreas Halvorsen first reported a position in Sage Therapeutics in Q3 2019 and held it in 1 quarter.
Andreas Halvorsen's Sage Therapeutics position peaked at $37M in Q3 2019.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Viking Global Investors's 13F filing for Q4 2019, filed 13 Feb 2020.